| ACURA PHARMACEUTICALS, INC<br>Form 8-K<br>May 01, 2015   |
|--|
| UNITED STATES  |
| SECURITIES AND EXCHANGE COMMISSION   |
| WASHINGTON, D. C. 20549  |
|  |
| FORM 8-K   |
| CURRENT REPORT   |
| Pursuant to Section 13 or 15(d) of the   |
| Securities Exchange Act Of 1934  |
| April 30, 2015   |
| Date of Report (Date of earliest event reported)   |
|  |
| ACURA PHARMACEUTICALS, INC.  |
| (Exact Name of Registrant as Specified in Charter)   |
| State of New York 1-10113 11-0853640   |
| (State of Other Jurisdiction (Commission File Number) (I.R.S. Employer of Incorporation)  Identification Number) |

| 2agai 7 milg. 760 777 777 1107 1207 1207 1707 1707 1707  |
|--|
| Palatine, Illinois 60067   |
| (Address of principal executive offices) (Zip Code)  |
|  |
| (847) 705-7709   |
| (Registrant's telephone number, including area code)   |
|  |
|  |
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
|  |
| " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  |
|  |
| " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)  |
|  |
| " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-J(b))   |
|  |
| " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-L(c))  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |

### Item 5.07 Submission of Matters to a Vote of Security Holders.

On April 30, 2015, we held our Annual Meeting of Shareholders at which the shareholders voted (i) for the election of Immanuel Thangaraj, Bruce F. Wesson, Robert B. Jones, William G. Skelly and George K. Ross to our Board of Directors for one-year terms; and (ii) for the ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2015 fiscal year ending December 31, 2014.

The results of the voting with respect to each matter voted upon, as applicable, are set forth below.

1. Election of Directors:

#### Broker

| <u>Nominee</u>     | <u>For</u> | <u>Withheld</u> | Non-Votes  |
|--------------------|------------|-----------------|------------|
| Robert B. Jones    | 26,824,939 | 1,676,866       | 14,750,351 |
| Bruce F. Wesson    | 27,947,407 | 554,398         | 14,750,351 |
| William Skelly     | 27,939,528 | 562,277         | 14,750,351 |
| Immanuel Thangaraj | 27,970,009 | 531,796         | 14,750,351 |
| George Ross        | 27,965,908 | 535,887         | 14,750,351 |
|                    |            |                 |            |

2. Ratification of Independent Registered Public Accounting Firm for 2013 Fiscal Year:

<u>For Against Abstentions</u> 42,845,195292,246114,695

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

### ACURA PHARMACEUTICALS, INC.

By: /s/ Peter A. Clemens

Peter A. Clemens

Senior Vice President & Chief Financial Officer

Date: April 30, 2015